• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Immune Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for Bertilimumab for the Treatment of Bullous Pemphigoid

    Jocelyn Aspa
    Jul. 30, 2018 08:36AM PST
    Pharmaceutical Investing

    Immune Pharmaceuticals (OTCQB:IMNP) has announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on its application for Orphan Drug Designation for bertilimumab for treating bullous pemphigoid (BP). As quoted in the press release: “We are pleased that the COMP has issued its opinion in …

    Immune Pharmaceuticals (OTCQB:IMNP) has announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on its application for Orphan Drug Designation for bertilimumab for treating bullous pemphigoid (BP).

    As quoted in the press release:

    “We are pleased that the COMP has issued its opinion in support of our request for orphan designation for bertilimumab for the treatment of bullous pemphigoid.” commented Immune’s Chief Medical and Operating Officer, Tony Fiorino, MD, PhD. “Our data suggest that blocking eotaxin-1 can have important clinical benefits for patients with moderate-to-extensive disease. We intend to make use of the enhanced regulatory support enabled by receiving orphan drug designation from the EMA as we prepare for our planned pivotal phase 2/3 study of bertilimumab in bullous pemphigoid, expected to launch in 2019.”

    The COMP’s positive opinion will be sent to the European Commission, which is expected to grant the orphan drug designation within 30 days.  In addition to a 10-year period of marketing exclusivity in the European Union (EU) after product approval, orphan designation also provides incentives for companies seeking to develop and market therapies that treat a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the EU, including reduced regulatory fees, protocol assistance from the EMA during product development, and direct access to the centralized authorization procedure, allowing companies to make a single application to the EMA and potentially to gain conditional approval.

    Click here to read the full press release.

    immune pharmaceuticalspharmaceutical investingeuropean medicines agency
    The Conversation (0)

    Go Deeper

    AI Powered
    Row of test tubes and pipette with chemical droplet chemical coming from it.

    Top 5 Small-cap Biotech Stocks of 2025

    Scientist with petri dish.

    Pharma Market Forecast: Top Trends for Pharma in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×